Inhibition of the expression of hepatitis A and B viruses (HAV and HBV) proteins by interferon in a human hepatocarcinoma cell line (PLC/PRF/5)

被引:12
作者
Berthillon, P
Crance, JM
Leveque, F
Jouan, A
Petit, MA
Deloince, R
Trepo, C
机构
[1] INSERM,U271,F-69424 LYON 03,FRANCE
[2] CTR RECH ARMEES,UNITE BIOL MOL,LA TRONCHE,FRANCE
[3] INSERM U 131,CLAMART,FRANCE
关键词
cell culture; hepatitis A virus; hepatitis B virus; interferon; liver cancer;
D O I
10.1016/S0168-8278(96)80322-9
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Aims/Methods: PLC/PRF/5 is a continuous human hepatocarcinoma cell line whose genome contains integrated HBV DNA and which secretes two of the hepatitis B virus envelope proteins (HBs and PreS2). This line is also susceptible to infection by hepatitis A virus and was therefore used to compare the effects of interferon on protein synthesis of these two viruses and to assess the interactions which occur between them during infection. Results: Results showed that recombinant interferon alpha 2-a inhibited the expression of the two hepatitis B virus envelope antigens (HBs and PreS2) and of the only hepatitis A virus antigen in a dose-dependent fashion. Comparison of the effect of interferon on antigenic protein production of these two viruses, showed stronger inhibition of hepatitis A virus capsid antigen than of hepatitis B virus envelope antigens. Infection with hepatitis A virus also downregulates the expression of the two hepatitis B virus proteins. Conclusions: Considering the absence of cytotoxic effects from the doses used, this study confirms the relevance of this cellular model for the study of antiviral cytokines in vitro. It also provides a further rationale for the clinical evaluation of the therapeutic potential of interferons in severe hepatitis cases due either to hepatitis A virus alone or to superinfection of hepatitis B virus carriers by hepatitis A virus.
引用
收藏
页码:15 / 19
页数:5
相关论文
共 19 条
[1]  
ALEXANDER JJ, 1976, S AFR MED J, V50, P2124
[2]   TYPE-I INTERFERONS INHIBIT HEPATITIS-B VIRUS-REPLICATION AND INDUCE HEPATOCELLULAR GENE-EXPRESSION IN CULTURED LIVER-CELLS [J].
CASELMANN, WH ;
MEYER, M ;
SCHOLZ, S ;
HOFSCHNEIDER, PH ;
KOSHY, R .
JOURNAL OF INFECTIOUS DISEASES, 1992, 166 (05) :966-971
[3]  
CRANCE JM, 1985, CR ACAD SCI III-VIE, V301, P361
[4]   INHIBITION OF HEPATITIS-A VIRUS-REPLICATION INVITRO BY ANTIVIRAL COMPOUNDS [J].
CRANCE, JM ;
BIZIAGOS, E ;
PASSAGOT, J ;
VANCUYCKGANDRE, H ;
DELOINCE, R .
JOURNAL OF MEDICAL VIROLOGY, 1990, 31 (02) :155-160
[5]  
CRANCE JM, 1985, J VIROL METHODS, V18, P193
[6]  
EVANGELOS A, 1989, ANN INTERN MED, V110, P838
[7]   CHANGING EPIDEMIOLOGY AND CLINICAL ASPECTS OF HEPATITIS-A [J].
FORBES, A ;
WILLIAMS, R .
BRITISH MEDICAL BULLETIN, 1990, 46 (02) :303-318
[8]   EXPRESSION OF THE TERMINAL PROTEIN REGION OF HEPATITIS-B VIRUS INHIBITS CELLULAR-RESPONSES TO INTERFERON-ALPHA AND INTERFERON-GAMMA AND DOUBLE-STRANDED-RNA [J].
FOSTER, GR ;
ACKRILL, AM ;
GOLDIN, RD ;
KERR, IM ;
THOMAS, HC ;
STARK, GR .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (07) :2888-2892
[9]  
GAUSSMULLER V, 1984, P SOC EXP BIOL MED, V175, P10, DOI 10.3181/00379727-175-41757
[10]   CLINICAL AND PROGNOSTIC DIFFERENCES IN FULMINANT-HEPATITIS TYPE-A, TYPE-B AND TYPE-NON-A-NON-B [J].
GIMSON, AES ;
WHITE, YS ;
EDDLESTON, ALWF ;
WILLIAMS, R .
GUT, 1983, 24 (12) :1194-1198